Best pharmaceutical companies in Cambridge, MA

5764914 Novartis International AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland.

Shire Pharmaceuticals, Inc. develops, manufactures, markets, and sells pharmaceutical products. It focuses on central nervous system, gastrointestinal, general products, renal diseases, and human genetic therapies. The company offers ADDERALL and ADDERALL XR for attention deficit hyperactivity disorder (ADHD); REMINYL for Alzheimer's; and CARBATROL for epilepsy. It also develops a range of treatments for ADHD to treat children, adolescents, and adults, as well as researches on non-scheduled compounds. The company markets its products to defined customer groups, such as specialist doctors. It has sales and marketing infrastructure with a portfolio of products targeting the United States, Canada, the United Kingdom, France, Germany, Ireland, Italy, and Spain markets. Shire Pharmaceuticals, Inc. has distributors in Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea, and Thailand. The company was incorporated in 2004 and is based in Wayne, Pennsylvania. Shire Pharmaceuticals, Inc. operates as a subsidiary of Shire plc.

Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd, a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business. Headquartered in Woodcliff Lake, New Jersey, they are dedicated to a tradition of genuine concern for people and are driven by the desire to help meet the diverse health care needs of patients and their families and caregivers. They are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd., which has a strong and lasting commitment to the U.S. market. Their heritage and mission have earned us recognition as an innovative, efficient, solution-oriented pharmaceutical company - a company that effectively works with healthcare professionals, hospitals and managed care organizations to develop and market specialty products that help address unmet needs. Their ability to forge strong alliances gives us a competitive edge. In the United States, their rapid growth and strong performance result from putting patients and their families first when making decisions and from empowering the people who manage their operations. Eisai employees personify their values of integrity, respect, professionalism, quality and teamwork.

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.

Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products in the healthcare field. The company operates through three business segments, including Consumer; Pharmaceutical and Medical Devices; and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women's Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. These products are marketed principally to the general public and sold both to wholesalers and directly to independent and chain retail outlets throughout the world. Pharmaceutical The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use by the general public. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX (topiramate), approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT (Epoetin alfa, sold outside the U.S. as EPREX), a biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral (risperidone), a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients, RISPERDAL CONSTA (risperidone), a long-acting injectable, and INVEGA (paliperdone) Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN (levofloxacin) and FLOXIN (ofloxacin), both in the anti-infective field; CONCERTA (methylphenidate HCl), a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal (fentanyl transdermal system, sold outside the U.S. as DUROGESIC), a treatment for chronic pain that offers a novel delivery system. Medical Devices and Diagnostics The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis' circulatory disease management products; DePuy's orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon's surgical care and women's health products; Ethicon Endo-Surgery's minimally invasive surgical products; LifeScan's blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics' professional diagnostic products and Vistakon's disposable contact lenses.

Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical treatments for metabolic and cardiovascular disease, central nervous system disease, respiratory and immunology, oncology, and general medicine areas. It offers products for the treatment of type II diabetes, hypertension, insomnia, Alzheimer s-type dementia, hyperuricemia and gout, peptic ulcer, acid reflux, multiple myeloma, prostate and breast cancer, endometriosis, cancer, malignant lymphoma, and major depressive disorder diseases. The company was founded in 1998 and is based in Deerfield, Illinois. It has business and sales operations in Europe, the Russian Federation, CIS, Japan, North America, Latin America, Asia, and internationally. Takeda Pharmaceuticals U.S.A., Inc. operates as a subsidiary of Takeda Pharmaceutical Company Limited.

Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases. The company is driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. Merck delivers vaccines, medications, and consumer and animal health products that can help millions around the world. Merck was founded in 1891 and is headquartered in Kenilworth, NJ.

Eli Lilly and Company is known for their high-quality medicines which are being distributed to 125 countries. Founded in 1876 by Col. Eli Lilly, this global pharmaceutical company remains committed to his vision through every aspect of their business and the people they serve, starting with those who take their medicines, and extending to health care professionals, employees and the communities in which they live. They currently have up to $1 billion in revenue and around 10,000 employees.

Vertex Pharmaceuticals is a biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals and Nutritionals. - The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). - The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Sumitomo Dainippon Pharma America, Inc. is a holding company, which through its subsidiaries, discovers, develops, and commercializes pharmaceutical products. The company was founded in 2009 and is based in Wilmington, Delaware. Sumitomo Dainippon Pharma America, Inc. was formerly known as Dainippon Sumitomo Pharma America Holdings, Inc. and changed its name to Sumitomo Dainippon Pharma America, Inc. in July 2017. Sumitomo Dainippon Pharma America, Inc. operates as a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

Corium International is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development.

Eagle Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the 505(b)(2) regulatory pathway.

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. This segment manages various aspects of clinical trials, including study and protocol design, case report form design, paper or electronic questionnaires design, patient enrollment, study monitoring and data collection, data analysis, report writing, and medical services. The PCMS segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, and good manufacturing practice compliance consulting; and market development, product development, and targeted communications services in support of product launch. Its consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. In addition, this segment provides reimbursement and market access services. The Perceptive segment provides information technology solutions comprising medical imaging and systems integration services; ClinPhone RTSM, CTMS, and DataLabs EDC products; Web-based portals; and patient diary applications. The company was founded in 1983 and is headquartered in Waltham, Massachusetts.

Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments.

Sanofi US is part of a leading global healthcare company that discovers, develops, produces and markets innovative therapies to help protect health and enhance people's lives. Along with the other U.S. affiliates, Genzyme, Sanofi Pasteur, Merial and Chattem, they work to prevent and treat the diseases they know about today, as well as those they may face tomorrow. Sanofi US, with headquarters in Bridgewater, New Jersey, employs more than 16,900 professionals throughout the country.

Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India. The Company manufactures generic active pharmaceutical ingredients that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe.

Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. Cold Genesys acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.